Drug intelligence / Profile preview

TENPA

Development stage: Phase 1
Modality: Nanoparticles → Drug Delivery Systems

Overview

TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) is a novel nanoparticle formulation of the chemotherapeutic agent paclitaxel. It is designed for tumor-specific delivery, encapsulating paclitaxel within a human serum albumin-haemin complex. This formulation aims to enhance paclitaxel accumulation in cancer tissue, thereby reducing systemic toxicity and improving therapeutic efficacy compared to existing paclitaxel formulations like Abraxane. TENPA was investigated for its safety and maximum tolerated dose in patients with advanced solid tumors.

Other names: Targeting-Enhancing Nanoparticles of Paclitaxel

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TENPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TENPA.

Explore the full profile